Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20661712 | 0.84 | TSHR (0.39) | TAAR1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL71434 | 0.82 | GABRA1 (0.38) | TAAR1LMNAGABRA1GABRG2GABRB3 | |
| SCHEMBL12533361 | 0.78 | ADRA2A (0.49) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL16746080 | 0.78 | ALDH1A1 (0.40) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL12533362 | 0.77 | ALDH1A1 (0.39) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL13035771 | 0.77 | ALDH1A1 (0.39) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL3115776 | 0.77 | ALDH1A1 (0.44) | TAAR1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL15479687 | 0.75 | ADRA2A (0.34) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL8306404 | 0.73 | NR3C2 (0.47) | ALDH1A1MAPTLMNAGABRA1GABRG2 | |
| SCHEMBL20756201 | 0.73 | ADRA2A (0.40) | ADRA2AADRA2CADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024108155-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3279187-B1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20170297999-A1 | METHOD FOR PRODUCING TRIPHENYLBUTENE DERIVATIVE | Shionogo & Co., Ltd (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170297999-A1 | METHOD FOR PRODUCING TRIPHENYLBUTENE DERIVATIVE | Shionogo & Co., Ltd (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170158704-A1 | PYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN-INHIBITORY ACTIVITY | THE UNIVERSITY OF TOKYO (JP) | 2017-06-08 | — | — | US | disclosed |
| US-20160257641-A1 | NOVEL ALKYLENE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2016-09-08 | — | — | US | disclosed |
| US-20160002247-A1 | 8-SUBSTITUTED IMIDAZOPYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY | THE UNIVERSITY OF TOKYO (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
| US-9066954-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-7645778-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | TAAR1 2644/4885ADRA2A 900/4885ADRA2C 677/4885 |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | TAAR1 4599/4885ADRA2A 3155/4885ADRA2C 2654/4885 |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | TAAR1 4599/4885ADRA2A 3155/4885ADRA2C 2654/4885 |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | TAAR1 263/4885ADRA2A 709/4885ADRA2C 794/4885 |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | ACSS2, ACACB, ACAT2 | TAAR1 1844/4885ADRA2A 401/4885ADRA2C 269/4885 |
| US-20170158704-A1 | PYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN-INHIBITORY ACTIVITY | ENPP2, ITPA, IMPA1 | TAAR1 2103/4885ADRA2A 2082/4885ADRA2C 2525/4885 |
| US-20170297999-A1 | METHOD FOR PRODUCING TRIPHENYLBUTENE DERIVATIVE | TERB1, TERT, PAH | TAAR1 695/4885ADRA2A 3730/4885ADRA2C 3599/4885 |
| US-20160002247-A1 | 8-SUBSTITUTED IMIDAZOPYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY | ENPP2, UACA, IAPP | TAAR1 4427/4885ADRA2A 2126/4885ADRA2C 2866/4885 |
| US-20160257641-A1 | NOVEL ALKYLENE DERIVATIVES | ACSS2, ACACB, ADCY2 | TAAR1 445/4885ADRA2A 311/4885ADRA2C 214/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | TAAR1 4599/4885ADRA2A 3155/4885ADRA2C 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.